Collaborations
Oral interferon rights licensed to Nobel to treat Behcet disease
Published in Medical Letter on the CDC and FDA, October 17th, 2004
Amarillo Biosciences, Inc., (AMAR) announced that the company has signed a licensing and supply agreement with Nobel Ilac Sanayii Ve Ticaret A.S., providing the rights to oral low-dose interferon-alpha for the treatment of Behcet disease in Turkey and in Azerbaijan, Bosnia & Herzegovina, Bulgaria, Croatia, Georgia, Kazakhstan, Kyrghyzstan, Macedonia, Romania, Russia, Saudi Arabia, Slovenia, Tajikistan, Turkmenistan, Uzbekistan, and Federal Republic of Yugoslavia.
The license agreement covers a territory whose population is approximately 365 million. In Turkey, where the disease is more than 600 times more prevalent than in the United States, there are from 56,000 to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Avian Influenza Vaccine
Vaccine development for potential avian influenza pandemic reviewed - Diagnostics
Proteomic pattern diagnostics has potential for diagnostics development - Diet and Nutrition
Dietary supplement use by U.S. adults reported - Hemorrhagic Fever
Ngari virus associated with outbreaks of hemorrhagic fever in Africa - Obesity Survival and Mortality
Methods of calculating deaths attributable to obesity compared - AIDS/HIV Therapy
Effort underway to improve the quality of HIV care in U.S. - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
